Retraction Notice

Title of retracted article: Exploring the Mechanism of Wu Ling San plus Flavor for the Treatment of Diabetic Macular Edema Based on Network Pharmacology and Molecular Docking Techniques

Authors: Kunmao Ke, Xiaoyun Jiang, Yun Zhang, Yekai Zhou, Jian Zhao, Junbiao Zhang, Yanli Liu, Meixia An

* Corresponding author. Email: Yanliliu1116@163.com anmeixia@163.com

Journal: Chinese Medicine
Year: 2022
Volume: 13
Number: 3
Pages (from - to): 33 - 50
DOI (to PDF): https://doi.org/10.4236/cm.2022.133004
Paper ID at SCIRP: 8801460
Article page: https://www.scirp.org/journal/paperinformation.aspx?paperid=120050
Retraction date: 2022-10-10

Retraction initiative (multiple responses allowed; mark with X):
- X All authors
- Some of the authors:
- Editor with hints from Journal owner (publisher)
- Reader:
- Other:

Date initiative is launched: 2022-10-10

Retraction type (multiple responses allowed):
- Unreliable findings
- Lab error
- Inconsistent data
- Analytical error
- Biased interpretation
- Other:
- Irreproducible results
- Failure to disclose a major competing interest likely to influence interpretations or recommendations
- Unethical research
- Fraud
- Data fabrication
- Fake publication
- Plagiarism
- Self plagiarism
- Overlap
- Redundant publication *
- Copyright infringement
- Other legal concern:
- Other legal concern:

Editorial reasons
- Handling error
- Unreliable review(s)
- Decision error
- Other:
- Other:

Results of publication (only one response allowed):
- are still valid.
- X were found to be overall invalid.

Author's conduct (only one response allowed):
- honest error
- academic misconduct
- none (not applicable in this case – e.g. in case of editorial reasons)
- * Also called duplicate or repetitive publication. Definition: "Publishing or attempting to publish substantially the same work more than once."
History
Expression of Concern:
☐ yes, date: yyyy-mm-dd
X no

Correction:
☐ yes, date: yyyy-mm-dd
X no

Comment:
The paper does not meet the standards of “Chinese Medicine”.

This article has been retracted to straighten the academic record. In making this decision the Editorial Board follows COPE’s Retraction Guidelines. Aim is to promote the circulation of scientific research by offering an ideal research publication platform with due consideration of internationally accepted standards on publication ethics. The Editorial Board would like to extend its sincere apologies for any inconvenience this retraction may have caused.

Editor guiding this retraction: Prof. Maythem Saeed (EiC of CM)
Exploring the Mechanism of Wu Ling San plus Flavor for the Treatment of Diabetic Macular Edema Based on Network Pharmacology and Molecular Docking Techniques

Kunmao Ke1*, Xiaoyun Jiang2*, Yun Zhang2*, Yekai Zhou2, Jian Zhao2, Junbiao Zhang2, Yanli Liu2#, Meixia An2#

1Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong, Shantou, China
2Department of Ophthalmology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China

Email: Yanliliu1116@163.com, anmeixia@163.com

Abstract
Aim: To explore the possible mechanism of action of Wu Ling San Plus for the treatment of diabetic macular edema (DME) through network pharmacology and molecular docking. Methods: DME-related genes were searched in drugbank database, GeneCards database, Online Mendelian Human Genetic (OMIM) database, and TTD database. The Traditional Chinese Medicine Systems Pharmacology (TCMSP) database was applied to screen for potential chemically active substances and related target proteins in the drug pairs. A “drug-disease target” regulatory network was constructed with Cytoscape (3.7.2) software, and a protein-protein interaction (PPI) network was established by Bisogenet and CytoNCA, followed by GO and KEGG enrichment analysis using the Bioconductor platform and R software. Finally, molecular docking of potential chemically active substances and key targets was performed using MOE software. Results: 63 compounds were screened from Wu Ling San Plus, including 71 targets for the treatment of DME, and the PPI core genes were AKT1, JUN, TP53, IL10, VEGFA, IL6, MMP9, CASP3, CCL2, PTGS2, MAPK8; GO biofunctional analysis contained 2143 enrichment results, mainly involving the hypoxic responses, the KEGG enrichment yielded 122 related signaling pathways consisting of the AGE-RAGE signaling pathway, cellular senescence pathway, TNF signaling pathway, IL-17 signaling pathway, C-type lectin receptor signaling pathway, FoxO signaling pathway, MAPK signaling pathway, T cell receptor signaling pathway, etc. Molecular

*Kunmao Ke, Xiaoyun Jiang and Yun Zhang contributed equally to this work.
#Corresponding authors.
docking results indicated that quercetin may have an effect on AKT1, TPP53, VEGFA, IL6, MMP9, CASP3, CCL2, PTGS2, and kaempferol also had a better binding ability to MAPK8. Conclusion: The treatment of DME with Wu Ling San Plus shows the multi-component and multi-target features of traditional Chinese medicine, which may achieve the management of DME’s developing process through many routes, offering certain insights and a foundation for further research.

**Keywords**

Diabetic Macular Edema, Diabetic Retinopathy, Wu Ling San plus Flavor, Alkaloids, Aliphatic, Network Pharmacology, Molecular Docking

### 1. Background

Diabetic macular edema (DME) currently is the primary cause [1]. The prevalent pathogenesis of DME is a disruption in the production and absorption of fluid in the retina, leading to increased accumulation of fluid between the layers of the retina, with exudate accumulating in the macula. The disruption of the Blood-Retinal Barrier caused by an increase in the Vascular Endothelial Growth Factor is regarded to be the fundamental pathophysiology of DME (VEGF). Anti-VEGF injections are the most frequent treatment for DME, however, due to variances in staging, severity, and the complexity of the concomitant retinal diseases, some patients have poor outcomes and the oedema is difficult and recurring to remove [2].

“Treatise on Typhoid Fever—Defining the Pulses and Symptoms of Sun Diseases,” by Wu Ling San. Only five plants are used in the original formula: Oriental Waterplantain rhizome, Polyporus, Atractylodes, Poria, and Cassia twig, which have the effects of warming yang, transforming qi, promoting water and permeating dampness, and are mainly used to treat the evidence of stagnation of water and dampness in the bladder, thus primary being used in modern times for the evidence of internal stagnation of water and dampness [3]. According to traditional Chinese medicine, the yellowish color of macula is ascribed to the spleen evidence, which prefers dryness and despises dampness, so if water and dampness cease inside the macula for an extended period of time, the middle yang will be obstructed, the spleen will be blocked, the spleen will be unable to transfer fluid, the qi will be weak, the water will flood and produce swelling, and the water and dampness will halt in the macular area, causing macular edema. Treatment for DME patients with long-term diabetes mellitus should include systemic and fundus identification, as well as the principles of nourishing yin and benefitting qi, as well as dipping dampness and strengthening the spleen [4] [5] [6].

The Wu Ling San formula was supplemented with Rehmannia glutinosa to nourish Yin and promote fluid, Milkvetch root to strengthen the spleen, tonify
Qi, and promote diuresis to reduce swelling, and fried Coix seed to strengthen the effect of diuresis and dampness to strengthen the spleen in this study. However, the target and mechanism of action remain unknown. Network pharmacology provides a comprehensive explanation of the pharmacological mechanisms underlying drug formulations, enabling time and labor-efficient enhancement of clinical efficacy as well as reduction of toxicity and side effects [7]. Additionally, molecular docking is a theoretical method to study the interaction and recognition between protein receptors and small molecule ligands owing to its capacity to predict the binding mode and affinity strength [8] [9] [10]. Network pharmacology, as a brand new subject based on system biology, bioinformatics, and high throughput histology, is getting more and more motivated [11] [12] [13]. Therefore, this study employed network pharmacology combined with molecular docking to explore the key genes and pathogenesis of Wu Ling San plus flavor for the treatment of DME, with the goal of identifying novel therapeutic targets.

2. Materials and Methods

2.1. Software and Databases

TCM Systematic Pharmacology Analysis Platform (TCMSP, http://tcmspw.com/tcmspw.php);
Drugbank database (https://go.drugbank.com/);
NCBI Gene database (https://www.ncbi.nlm.nih.gov/gene/); GeneCards database (https://www.genecards.org/);
Online Mendelian Inheritance in Man (OMIM) database (http://www.omim.org/);
TTD database (http://db.idrblab.net/ttd/);
RCSB PDB database (http://www.rcsb.org/);
Cytoscape software (Version 3.7.2); Rgui software (Version 3.6.2); MOE software (Version 2015.10).

2.2. Methods

2.2.1. Screening for DME-Related Genes

DME-related targets were collected in the drugbank database, NCBI Gene database, GeneCards database, OMIM database, and TTD database, respectively, using the Diabetic Macular Edema keyword, and Merge was performed after removing duplicates.

2.2.2. Active Ingredient Screening and Target Prediction

TCMSP was used to screen the compounds for the activity of Polyporus, Atractylodes, Poria, Cassia twig, Rehmannia glutinosa, Milkvetch root, and Coix seeds using bioavailability (OB) and drug-like properties (DL). The activity screening was performed to select those that satisfied both OB ≥ 30% and DL ≥ 0.18 [14] as potential active ingredients. The TCMSP was then adopted to identify the active component targets in each herbal remedy.
2.2.3. Regulatory Network
The interaction targets, the prospective targets of action of Wu Ling San plus flavor on potential active ingredients associated with DME, and the disease differential genes acquired from the screening were compared and analyzed using Perl language. The compound names, target gene names, main biological functions, and signaling pathways were then imported into Cytoscape 3.7.2 software to map the regulatory network of Wu Ling San plus flavor.

2.2.4. Protein-Protein Interaction Network Construction
The identities of interacting target genes of drugs and diseases were imported into Cytoscape 3.7.2 software, and the Bisogenet package was installed to construct protein interaction (PPI) networks [15], followed by the CytoNCA package for network topology analysis.

2.2.5. GO Biofunctional Enrichment Analysis
The ID-transformed target genes acquired after network merging were then submitted to GO enrichment analysis using the Bioconductor platform and R software to assess the protein groups included in each GO annotation with a p-value and indicate the relevance of the protein biological functions. Biological process (BP), molecular function (MF), and cellular composition (CC) were selected. Bubble maps were plotted in 3 modules.

2.2.6. KEGG Metabolic Pathway Enrichment Analysis
The Bioconductor platform and R software were applied to perform KEGG metabolic pathway enrichment analysis on the target genes of drug-disease interaction to determine key metabolic pathways of action of Wu Ling San plus flavor for the treatment of DME.

2.2.7. Molecular Docking Validation
The chemical structures of the active ingredients of Wu Ling San plus flavor in mol2 format were obtained by searching in the TCMSP database, the protein crystal structures were obtained from the RCSB PDB database (http://www.rcsb.org/), and the original ligands or inhibitors of c-Jun, PPARG, NR3C1, RXRA, BCL2 were also searched. The MOE 2015.10 software was utilized for the chemical components with greater than average degree values in the active component-target of action network and the PPI network for c-Jun, PPARG, NR3C1, RXRA, BCL2 (c-JUN crystal structure PDB: 4W4V, PPARG crystal structure PDB: 3ADT, NR3C1 crystal structure PDB: 3ADT, NR3C1 crystal structure PDB: 4LSJ, RXRA crystal structure PDB: 3NSQ, BCL2 crystal structure PDB: 4IEH) were molecularly docked to obtain the corresponding docking data and the docking data of c-JUN, PPARG, NR3C1, RXRA, BCL2 with their original ligands or inhibitors. The value of binding energy was used to measure the docking impact between the active component and the primary target and the interactions between the drug molecules and protein crystals were analyzed by planar molecular interaction maps and three-dimensional interac-
tion pattern maps.

3. Results

3.1. Acquisition of DME-Related Targets

DME-related targets were collected from five databases, namely drugbank database, NCBI Gene database, GeneCards database, OMIM database, and TTD database with the Diabetic Macular Edema keyword, respectively, and 35, 33, 11, 905, and 17 DME-related targets were combined after removing duplicates to obtain a total of 957 DME-related targets.

3.2. Drug-Disease Target Prediction

From the TCMSP database, 31, 55, 34, 220, 87, 76, and 38 compounds were searched for Polyporus, Atractylodes, Poria, Cassia twig, Rehmannia glutinosa, Milkvetch Root, and Coix seeds, respectively, and 63 were finally selected based on bioavailability (OB) ≥ 30% and drug-like properties (DL) ≥ 0.18, derived from Polyporus with 11, atracyctodes with 7, Poria with 15, Cassia Twig with 7, Milkvetch Root with 20, Rehmannia glutinosa with 2, and Coix seeds with 9, as shown in Table 1. The target proteins of the selected compounds were obtained from the TCMSP database, and their corresponding gene names were searched in the UniProt database, the DME-related genes got from the joint screening of related databases, and 61 genes were acquired from the intersection of the two, as shown in Figure 1.

3.3. Therapeutic DME Regulatory Network Construction

A drug compound-acting target disease network with 35 nodes was constructed using Cytoscape 3.7.2 software (Figure 2), in which purple, yellow, green, cyan, blue, red, and pink nodes represent the main active compounds of DME, C. multiflora, Poria, Cassia, Dioscorea, Astragalus, and Coix seeds, respectively, and blue nodes represent potential targets, with each edge indicating compound and target The interaction relationship between compounds and targets. It can be seen that MOL000098 (quercetin) and MOL000422 (kaempferol) play a key role in the whole network and may be the core compounds of the Angelica-Chuanxiong drug pair for the treatment of DME.

![Figure 1](image_url) Venn diagram of Wu Ling San plus flavor and DME genes.
Table 1. 63 active compounds in Wuling powder with added flavor.

| Number | Encoding | Name                                                                 | OB/% | DL  |
|--------|----------|----------------------------------------------------------------------|------|-----|
| 1      | MOL000020| 12-senecioyl-2E,8E,10E-atractylentriol                               | 62.40| 0.22|
| 2      | MOL000021| 14-acetyl-12-senecioyl-2E,8E,10E-atractylentriol                    | 60.31| 0.31|
| 3      | MOL000022| 14-acetyl-12-senecioyl-2E,8Z,10E-atractylentriol                    | 63.37| 0.30|
| 4      | MOL000028| α-Amyrin                                                              | 39.51| 0.76|
| 5      | MOL000033| (24S)-24-Propylcholesta-5-Ene-3β-Ol                                  | 36.23| 0.78|
| 6      | MOL000049| 3β-acetoxyatractylene                                                | 54.07| 0.22|
| 7      | MOL000072| 8β-ethoxy atracylenolide III                                         | 35.95| 0.21|
| 8      | MOL000073| ent-Epicatechin                                                       | 48.96| 0.24|
| 9      | MOL000098| quercetin                                                             | 46.43| 0.28|
| 10     | MOL000211| Mairin                                                                | 55.38| 0.78|
| 11     | MOL000239| Jaranol                                                               | 50.83| 0.29|
| 12     | MOL000273| 16α-Hydroxydehydrottrametenolic acid                                 | 30.93| 0.81|
| 13     | MOL000275| trametenolic acid                                                    | 38.71| 0.80|
| 14     | MOL000276| 7,9(11)-dehydropachymic acid                                         | 35.11| 0.81|
| 15     | MOL000279| Cerevisterol                                                          | 37.96| 0.77|
| 16     | MOL000280| (2R)-2-[(3S,5R,10S,14R,16R,17R)-3,16-dihydroxy-4,4,10,13,14-pentamethyl-2,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-5-isopropyl-hex-5-enolic acid | 31.07| 0.82|
| 17     | MOL000282| ergosta-7,22E-dien-3β-ol                                              | 43.51| 0.72|
| 18     | MOL000283| Ergosterol peroxide                                                  | 40.36| 0.81|
| 19     | MOL000285| (2R)-2-[(5R,10S,13R,14R,16R,17R)-16-hydroxy-3-keto-4,4,10,13,14-pentamethyl-1,2,5,6,12,15,16,17-octahydrocyclopenta[a]phenanthren-17-yl]-5-isopropyl-hex-5-enolic acid | 38.26| 0.82|
| 20     | MOL000287| 3β-Hydroxy-24-methylene-8-lanostene-21-oic acid                      | 38.70| 0.81|
| 21     | MOL000289| pachymic acid                                                        | 33.63| 0.81|
| 22     | MOL000290| Poricoic acid A                                                      | 30.61| 0.76|
| 23     | MOL000291| Poricoic acid B                                                      | 30.52| 0.75|
| 24     | MOL000292| poricoic acid C                                                      | 38.15| 0.75|
| 25     | MOL000296| hederagenin                                                          | 36.91| 0.75|
| 26     | MOL000300| dehydroeburicoic acid                                                | 44.17| 0.83|
| 27     | MOL000354| isorhamnetin                                                         | 49.60| 0.31|
| 28     | MOL000358| β-sitosterol                                                         | 36.91| 0.75|
| 29     | MOL000359| sitosterol                                                           | 36.91| 0.75|
|   | Compound ID    | Name                                                   | Retention Time | Peak Area   |
|---|----------------|--------------------------------------------------------|----------------|-------------|
| 30| MOL000371      | 3,9-di-O-methylnissolin                               | 53.74          | 0.48        |
| 31| MOL000374      | 5’-hydroxyso-muronatulol-2’,5’-di-O-glucoside         | 41.72          | 0.69        |
| 32| MOL000378      | 7-O-methylisomuronatulol                               | 74.69          | 0.30        |
| 33| MOL000379      | 9,10-dimethoxypterocarpan-3-O-β-D-glucoside          | 36.74          | 0.92        |
| 34| MOL000380      | (6aR,11aR)-9,10-dimethoxy-6a,11a-dihydro-6H-benzofurano [3,2-c]chromen-3-ol | 64.26          | 0.42        |
| 35| MOL000387      | Bifendate                                             | 31.10          | 0.67        |
| 36| MOL000392      | formononetin                                          | 69.67          | 0.21        |
| 37| MOL000398      | isoflavanone                                          | 109.99         | 0.30        |
| 38| MOL000417      | Calycosin                                             | 47.75          | 0.24        |
| 39| MOL000422      | kaempferol                                            | 41.88          | 0.24        |
| 40| MOL000433      | FA                                                    | 68.96          | 0.71        |
| 41| MOL000438      | (3R)-3-(2-hydroxy-3,4-dimethoxyphenyl)chromen-7-ol    | 67.67          | 0.26        |
| 42| MOL000439      | isomuronatulol-7,2’-di-O-glucosiole                   | 49.28          | 0.62        |
| 43| MOL000442      | 1,7-Dihydroxy-3,9-dimethoxy pterocarpenen             | 39.05          | 0.48        |
| 44| MOL000449      | Stigmasterol                                          | 43.83          | 0.76        |
| 45| MOL000492      | (+)-catechin                                          | 54.83          | 0.24        |
| 46| MOL000796      | (22E,24R)-ergosta-6-en-3β,5α,6β-triol                | 30.20          | 0.76        |
| 47| MOL000797      | (22E,24R)-ergosta-7,22-dien-3-one                     | 44.88          | 0.72        |
| 48| MOL000798      | ergosta-7,22-diene-3β-ol                              | 43.51          | 0.72        |
| 49| MOL000801      | 3α,8α-epidioxy-(22E,24R)-ergosta-6,22-dien-3β-ol     | 44.39          | 0.82        |
| 50| MOL000816      | ergosta-7,22-dien-3-one                               | 44.88          | 0.72        |
| 51| MOL000817      | ergosta-5,7,22-trien-3-ol                             | 46.18          | 0.72        |
| 52| MOL000820      | polyporosterone E                                     | 45.71          | 0.85        |
| 53| MOL000822      | polyporosterone G                                     | 33.43          | 0.81        |
| 54| MOL000955      | CLR                                                   | 37.87          | 0.68        |
| 55| MOL001323      | Sitosterol α                                          | 43.28          | 0.78        |
| 56| MOL001494      | Mandenol                                              | 42.00          | 0.19        |
| 57| MOL001736      | (-)-taxifolin                                         | 60.51          | 0.27        |
| 58| MOL002372      | (6Z,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetrasa-2,6,10,14,18,22-hexaene | 33.55          | 0.42        |
| 59| MOL002882      | [(2R)-2,3-dihydroxypropyl] (Z)-octadec-9-enoate       | 34.13          | 0.30        |
| 60| MOL004576      | taxifolin                                             | 57.84          | 0.27        |
| 61| MOL008118      | Coixenolide                                           | 32.40          | 0.43        |
| 62| MOL008121      | 2-Monoolein                                           | 34.23          | 0.29        |
| 63| MOL011169      | Peroxyergosterol                                      | 44.39          | 0.82        |
3.4. PPI Network Analysis

The 71 intersecting target genes obtained from drug-disease mapping were imported into the String database for PPI network analysis before the topological analysis was performed by CytoNCA in Cytoscape 3.7.2 (Figure 3(a)), showing the original 71 nodes, filtering the core network based on mediator closeness, degree, eigenvector, and LAC > median (Figure 3(b)), and then filtering the filtered network again until no more filtering is possible. The final screened network (Figure 3(c)) has 11 nodes and 55 edges, where the nodes represent proteins. From the final screened core network, it can be seen that AKT1, JUN, TP53, VEGFA, IL6, MMP9, CASP3, CCL2, PTGS2, MAPK8 play an important linkage role in the PPI network and may be the most important potential target of Wuling Sanga for the treatment of DME.

3.5. GO Enrichment Analysis

To further elucidate the possible roles of candidate targets, GO enrichment analysis was performed using the Bioconductor platform and R software, and 2143 GO entries were identified (p < 0.05). Among them, the largest number of entries related to biological processes (BP) with 2019 entries, mainly related to response to hypoxia, response to reduced oxygen levels, regulation of apoptotic signaling pathways, response to metal ions, regulation of DNA-binding transcription factor activity, regulation of reactive oxygen metabolic processes, cellular response to oxidative stress, and reproductive system development; molecular function (MF)-related entries with 92 entries, mainly in each GOs The top 20 entries with the highest P-values are presented in the form of a bar chart, see Figure 4 indicating that the longer length represents a higher number of genes, indicating the higher importance of the entry.
Figure 3. PPI network of Wu Ling San plus flavor and DME intersection targets.
3.6. KEGG Enrichment Analysis

KEGG enrichment analysis was performed on 71 putative action targets using the Bio conductor platform and R language, yielding a total of 122 entries. The top 20 entries with small P-values are shown in Figure 5, which are presented in the form of bar graph plots. The length and color of the bar graph show significance; the greater the length, the more genes are represented, suggesting that the entry is more important. It can be seen that the relevant mechanisms mainly involve the AGE-RAGE signaling pathway, cellular senescence pathway, TNF signaling pathway, IL-17 signaling pathway, C-type lectin receptor signaling pathway, FoxO signaling pathway, MAPK signaling pathway, T cell receptor signaling pathway, etc.

3.7. Molecular Docking

The ligands in the proteins were isolated using Pymol (version 2.3.4), and the 11 proteins in Figure 3(c) were docked to quercetin and kaempferol compounds using AutoDock Vina, with binding energies (affinity) $-7.0$ kcal·mol$^{-1}$ indicating good binding activity [16] and the lower the binding energy, the better the docking is indicated. As shown in Table 2, a total of 2 out of 11 proteins have binding energy $< -7.0$ kcal·mol$^{-1}$ to the corresponding compounds, indicating that these proteins have a strong affinity for the compounds. Figure 6 presents...
Figure 5. KEGG pathway analysis.

Figure 6. Partial diagram of molecular docking: (a) JUN-quercetin; (b) IL-10-quercetin.

Table 2. Docking results of active compounds and potential targets.

| Target point | Chemical compound | Binding energy/(kcal-mol⁻¹) |
|--------------|-------------------|-----------------------------|
| JUN          | quercetin         | −5.5                        |
| IL10         | quercetin         | −6.7                        |

the docking complex of the eleven targets together with their strongest binding components.
4. Discussion

Network pharmacology, which is based on the theory of systems biology, uses various methods such as histology and network visualization to create system network models to examine the intervention and impact of drugs on diseases from a holistic perspective and reveal the complex relationships between drugs, diseases, targets, and pathways, which are important for understanding the mechanism of action, the material basis of pharmacological effects, and the development of new drugs [17] [18] [19] [20] [21].

In the present study, TCM active component-target network analysis revealed that quercetin, kaempferol, and other active ingredients can act on multiple targets in the network. This data implies that these components are significant for Wu Ling San Plus’s therapeutic impact on DME and should be investigated further. Quercetin has the most potential targets. According to previous reports, quercetin, one of the most prominent members of the natural flavonoid family, has been reported to be beneficial in age-related ophthalmopathy and retinal ischemia-reperfusion injury [22] [23], whose protective effect on retinopathy was mainly attributed to its anti-oxidative, anti-inflammatory, anti-apoptotic, anti-angiogenic and neuroprotective effects in retinal cells [24] [25] [26].

The main proteins of the PPI network, AKT1, JUN, VEGFA, MMP9, and CASP3, were evaluated in this study, revealing that the active components of Wu Ling San Plus had strong binding activity to them and can be exploited as prospective targets for the treatment of DME. Anti-VEGF therapy is currently a popular therapeutic option for DME. CASP3, a crucial executor downstream of the apoptotic pathway, performs a last executive function in the JUN apoptotic pathway [27] [28] [29]. MMPs are a family of Zn²⁺-dependent endopeptidases that degrade all ECM components except polysaccharides, promote cell proliferation, neovascularization, and tissue remodeling, and MMP-9 is one of the most important members of the MMPs family, playing an essential role in the formation of DR.

The GO enrichment study produced intriguing findings and illustrated the complexity of DME pathogenesis. First, the target genes were found to be enriched in response to hypoxic stress, which may be directly influenced by sugar metabolism. Clinical and experimental studies have demonstrated that hyperglycemia is the primary factor leading to the pathogenesis of diabetic complications [30]. Oxidative stress can damage cell membrane integrity [31], inducing apoptosis, microvascular damage, and barrier damage and ultimately leading to DR development. 10 most important GO (BP) entries are mainly related to hypoxic response, oxygen level reduction response, apoptotic signaling pathway regulation, metal ion response, regulation of DNA-binding transcription factor activity, regulation of reactive oxygen metabolic processes, cellular oxidative stress response, and reproductive system development. Related studies have shown that the occurrence and development of DME are associated with cellular dysfunction and injury, chronic inflammatory infiltration, and oxidative stress [32] [33] [34] [35]. 92 molecular function (MF)-related entries, mainly related to
cytokine activity, nuclear receptor activity, ligand-activated transcription factor activity, steroid hormone receptor activity, growth factor receptor binding, etc; 32 entries related to cell composition (CC), mainly associated with membrane rafts, transcription factor complexes, endoplasmic reticulum lumen, etc.

KEGG metabolic pathway shows that its mechanism of action is mainly related to the AGE-RAGE signaling pathway, cellular senescence pathway, TNF signaling pathway, IL-17 signaling pathway, C-type lectin receptor signaling pathway, FoxO signaling pathway, MAPK signaling pathway, T cell receptor signaling pathway. The pathogenesis of DME is complex, which was linked to the breakdown of the inner BRB, as well as the malfunctioning of Müller cells and RPE. Müller cell, like a pump, drains ions and water into the vitreous body and retinal blood vessels with the support of normal distribution and function of Kir4.1 and AQP4. Müller cells, also the major glial cells in the retina, play a critical role in maintaining the structure and normal functions of the retina with highly expressed RAGE [36]. In addition, a study demonstrated that RAGE is of great significance in retinal neurodegeneration induced by diabetes and that early induction of RAGE expression by hyperglycemia in retinal Müller cells contributes to the increased levels of proinflammatory cytokines, including VEGF (a crucial downstream growth factor in angiogenesis) and monocyte chemoattractant protein-1 (MCP-1), both in vivo and in vitro [37]. Another common and well-known pathway, the TNF signaling pathway, is closely related to inflammation, which is a crucial process in DME progression [38]. Gao's study revealed that hypoxia-inducible factor subtype 1α in diabetic retina is likely to play a role in dysfunction and vulnerability related to DR progression via TNF-α [39].

5. Conclusion

The treatment of DME with Wu Ling San Plus shows the multi-component and multi-target features of traditional Chinese medicine, which may achieve the management of DME’s developing process through many routes, offering certain insights and a foundation for further research.

Authors’ Contributions

Yanli Liu and Meixia An had full access to all study data and take responsibility for its integrity and the accuracy of the analysis. Kunmao Ke, Xiaoyun Jiang and Yun Zhang were responsible for the study concept and design. Yekai Zhou, Jian Zhao and Junbiao Zhang responsible for data acquisition, extraction and drafting the paper, which was revised by Yanli Liu and Meixia An. Yanli Liu and Meixia An supervised the study. All authors read and approved the final manuscript.

Availability of Data and Materials

The datasets used and/or analysed during the current study are available fromDOI: 10.4236/cm.2022.133004
the corresponding author on reasonable request.

Conflicts of Interest

The authors declare no competing interests regarding the publication of this manuscript.

References

[1] Wong, T.Y., Sun, J., Kawasaki, R., et al. (2018) Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-Up, Referral, and Treatment Based on Resource Settings. *Ophthalmology, 125*, 1608-1622. https://doi.org/10.1016/j.ophtha.2018.04.007

[2] Das, A., McGuire, P.G. and Rangasamy, S. (2015) Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets. *Ophthalmology, 122*, 1375-1394. https://doi.org/10.1016/j.ophtha.2015.03.024

[3] Gu, H.R. and Jia, C.H. (2011) Analysis of Wulingsan Prescription. *Journal of Shandong University of Traditional Chinese Medicine, 35*, 208-209.

[4] Hu, Z., Xie, C., Yang, M., et al. (2021) Add-On Effect of Qiming Granule, a Chinese Patent Medicine, in Treating Diabetic Macular Edema: A Systematic Review and Meta-Analysis. *Phytotherapy Research, 35*, 587-602. https://doi.org/10.1002/ptr.6844

[5] Fu, Y.Y., Liu, Q.F. and Pu, Z.X. (2007) Clinical Study of Chronic Glomerulonephritis Proteinuria. *Journal of Changchun University of Traditional Chinese Medicine, No. 1*, 42.

[6] State Administration of Traditional Chinese Medicine (1994) Diagnostic and Therapeutic Standards for Chinese Medicine. *Journal of Chinese Medicine Management, No. 6*, 2.

[7] Hopkins, A.L. (2008) Network Pharmacology: The Next Paradigm in Drug Discovery. *Nature Chemical Biology, 4*, 682-690. https://doi.org/10.1038/nchembio.118

[8] Zhang, Y.Q. and Li, S. (2015) Some Advances in Network Pharmacology and Modern Research of Traditional Chinese Medicine. *Chinese Journal of Pharmacology and Toxicology, 29*, 883-892.

[9] Goh, K.I., Cusick, M.E., Valle, D., Childs, B., Vidal, M. and Barabási, A.L. (2007) The Human Disease Network. *Proceedings of the National Academy of Sciences of the United States of America, 104*, 8685-8690. https://doi.org/10.1073/pnas.0701361104

[10] Liu, Z.H. and Sun, X.B. (2012) Network Pharmacology: New Opportunity for the Modernization of Traditional Chinese Medicine. *Acta Pharmacuetica Sinica, 47*, 696-703.

[11] Xue, L.C., Dobbs, D., Bonvin, A.M. and Honavar, V. (2015) Computational Prediction of Protein Interfaces: A Review of Data Driven Methods. *FEBS Letters, 589*, 3516-3526. https://doi.org/10.1016/j.febslet.2015.10.003

[12] Villoutreix, B.O., Bastard, K., Sperandio, O., et al. (2008) In Silico-In Vitro Screening of Protein-Protein Interactions: Towards the Next Generation of Therapeutics. *Current Pharmaceutical Biotechnology, 9*, 103-122. https://doi.org/10.2174/138920108783955218

[13] Vakser, I.A. (2014) Protein-Protein Docking: From Interaction to Interactome. *Biophysical Journal, 107*, 1785-1793. https://doi.org/10.1016/j.bpj.2014.08.033
[14] Ru, J., Li, P., Wang, J., et al. (2014) TCMSp: A Database of Systems Pharmacology for Drug Discovery from Herbal Medicines. Journal of Cheminformatics, 6, Article No. 13. https://doi.org/10.1186/1758-2946-6-13

[15] Jeong, H., Mason, S.P., Barabási, A.L. and Oltvai, Z.N. (2001) Lethality and Centrality in Protein Networks. Nature, 411, 41-42. https://doi.org/10.1038/35075138

[16] Trott, O. and Olson, A.J. (2010) AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading. Journal of Computational Chemistry, 31, 455-461. https://doi.org/10.1002/jcc.21334

[17] Zhang, Q., Xu, Y., Peng, W., et al. (2020) To Study the Molecular Mechanism of Guizhi Shao Yao Zhimu Decoction in the Treatment of Rheumatoid Arthritis by Molecular Docking and Network Pharmacology. Chinese Herbal Medicine, 51, 4673-4684.

[18] Zhu, N., Sha, Z.J., He, J.W., et al. (2020) Discovery and Study of the Potential Value of Uncaria Eucommia Drugs in the Treatment of Pregnancy Hypertension Based on Network Pharmacology and Molecular Docking. China Journal of Chinese Materia Medica, 45, 5393-5402.

[19] Zhou, M.L., Huang, X.Y., Chen, Y.L., et al. (2020) To Explore the Mechanism and Experimental Verification of Si Jun Zi Decoction in the Treatment of Ulcerative Colitis Based on Network Pharmacology. China Journal of Chinese Materia Medica, 45, 5362-5372.

[20] Wang, H.Z., Gao, G., Yang, Q.Q., et al. (2020) To Explore the Therapeutic Mechanism of Rehmannia officinalis and Corni officinalis on Sequelea Stage of Ischemic Stroke Based on Network Pharmacology Technology. China Journal of Chinese Materia Medica, 45, 5920-6027.

[21] Bungau, S., Abdel-Daim, M.M., Tit, D.M., et al. (2019) Health Benefits of Polyphenols and Carotenoids in Age-Related Eye Diseases. Oxidative Medicine and Cellular Longevity, 2019, Article ID: 9783429. https://doi.org/10.1155/2019/9783429

[22] Arikan, S., Ersan, L., Karaca, T., et al. (2015) Quercetin Protects the Retina by Reducing Apoptosis Due to Ischemia-Reperfusion Injury in a Rat Model. Arquivos Brasileiros de Oftalmologia, 78, 100-104. https://doi.org/10.5935/0004-2749.20150026

[23] Lupo, G., Cambria, M.T., Olivieri, M., et al. (2019) Anti-Angiogenic Effect of Quercetin and Its 8-methyl Pentamethyl Ether Derivative in Human Microvascular Endothelial Cells. Journal of Cellular and Molecular Medicine, 23, 6565-6577. https://doi.org/10.10111/jccmm.14455

[24] Ola, M.S., Ahmed, M.M., Shams, S. and Al-Rejaie, S.S. (2017) Neuroprotective Effects of Quercetin in Diabetic Rat Retina. Saudi Journal of Biological Sciences, 24, 1186-1194. https://doi.org/10.1016/j.sjbs.2016.11.017

[25] Zhao, L., Sun, J., Shi, S., Qin, X., Zhang, K. and Xu, J. (2020) Kaempferol Protects Retinal Ganglion Cells from High-Glucose-Induced Injury by Regulating Vashobin-1. Neuroscience Letters, 716, Article ID: 134633. https://doi.org/10.1016/j.neulet.2019.134633

[26] Xu, X.H., Zhao, C., Peng, Q., Xie, P. and Liu, Q.H. (2017) Kaempferol Inhibited VEGF and PGF Expression and in Vitro Angiogenesis of HRECs under Diabetic-Like Environment. Brazilian Journal of Medical and Biological Research, 50, e5396. https://doi.org/10.1590/1414-431x20165396

[27] Tarantino, G. and Caputi, A. (2011) JNKs, Insulin Resistance and Inflammation: A
Possible Link between NAFLD and Coronary Artery Disease. *World Journal of Gastroenterology*, **17**, 3785-3794. [https://doi.org/10.3748/wjg.v17.i33.3785](https://doi.org/10.3748/wjg.v17.i33.3785)

[28] Chen, F. (2012) JNK-Induced Apoptosis, Compensatory Growth, and Cancer Stem Cells. *Cancer Research*, **72**, 379-386. [https://doi.org/10.1158/0008-5472.CAN-11-1982](https://doi.org/10.1158/0008-5472.CAN-11-1982)

[29] Su, C.C., Chen, J.Y., Din, Z.H., *et al.* (2014) 13-Acetoxysarcocassolidone Induces Apoptosis on Human Gastric Carcinoma Cells through Mitochondria-Related Apoptotic Pathways: p38/JNK Activation and PI3K/AKT Suppression. *Marine Drugs*, **12**, 5295-5315. [https://doi.org/10.3390/md12105295](https://doi.org/10.3390/md12105295)

[30] Cade, W.T. (2008) Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting. *Physical Therapy*, **88**, 1322-1335. [https://doi.org/10.2522/ptj.20080008](https://doi.org/10.2522/ptj.20080008)

[31] Bonnefont-Rousselot, D. (2002) Glucose and Reactive Oxygen Species. *Current Opinion in Clinical Nutrition & Metabolic Care*, **5**, 561-568. [https://doi.org/10.1097/00075197-200209000-00016](https://doi.org/10.1097/00075197-200209000-00016)

[32] Behl, T., Kaur, I. and Kotwani, A. (2016) Implication of Oxidative Stress in Progression of Diabetic Retinopathy. *Survey of Ophthalmology*, **61**, 187-196. [https://doi.org/10.1016/j.survophthal.2015.06.001](https://doi.org/10.1016/j.survophthal.2015.06.001)

[33] Kwon, J.W. and Jee, D. (2018) Aqueous Humor Cytokine Levels in Patients with Diabetic Macular Edema Refractory to Anti-VEGF Treatment. *PLOS ONE*, **13**, e0203408. [https://doi.org/10.1371/journal.pone.0203408](https://doi.org/10.1371/journal.pone.0203408)

[34] Noma, H., Yasuda, K. and Shimura, M. (2021) Involvement of Cytokines in the Pathogenesis of Diabetic Macular Edema. *International Journal of Molecular Sciences*, **22**, 3427. [https://doi.org/10.3390/ijms22073427](https://doi.org/10.3390/ijms22073427)

[35] Vinores, S.A., Derevjanik, N.L., Ozaki, H., Okamoto, N. and Campochiaro, P.A. (1999) Cellular Mechanisms of Blood-Retinal Barrier Dysfunction in Macular Edema. *Documenta Ophthalmologica*, **97**, 217-228. [https://doi.org/10.1023/A:1002136712070](https://doi.org/10.1023/A:1002136712070)

[36] Fletcher, E.L., Phipps, J.A., Ward, M.M., Puthussery, T. and Wilkinson-Berka, J.L. (2007) Neuronal and Glial Cell Abnormality as Predictors of Progression of Diabetic Retinopathy. *Current Pharmaceutical Design*, **13**, 2699-2712. [https://doi.org/10.2174/138161207781662920](https://doi.org/10.2174/138161207781662920)

[37] Zong, H., Ward, M., Madden, A., Yong, P.H., *et al.* (2010) Hyperglycaemia-Induced Pro-Inflammatory Responses by Retinal Müller Glia Are Regulated by the Receptor for Advanced Glycation End-Products (RAGE). *Diabetologia*, **53**, 2656-2666. [https://doi.org/10.1007/s00125-010-1900-z](https://doi.org/10.1007/s00125-010-1900-z)

[38] Starace, V., Battista, M., Brambati, M., *et al.* (2021) The Role of Inflammation and Neurodegeneration in Diabetic Macular Edema. *Therapeutic Advances in Ophthalmology*, **13**, https://doi.org/10.1177/25158414211055963

[39] Chung, Y.R., Kim, Y.H., Ha, S.J., *et al.* (2019) Role of Inflammation in Classification of Diabetic Macular Edema by Optical Coherence Tomography. *Journal of Diabetes Research*, **2019**, Article ID: 8164250. [https://doi.org/10.1155/2019/8164250](https://doi.org/10.1155/2019/8164250)
Abbreviations

TCMSP: Traditional Chinese Medicine System Pharmacology Database and Analysis Platform;
GO: Gene Ontology;
KEGG: Kyoto Encyclopedia of Genes and Genomes;
OB: Oral Bioavailability;
DL: Drug-Likeness.